Skip to main content
Premium Trial:

Request an Annual Quote

Flagship Biosciences TissueInsight

Flagship Biosciences has launched a new clinical diagnostics immuno-oncology service called TissueInsight, which provides CLIA-reportable PD-L1 results along with data about a tumor's microenvironment to pathologists, oncologists, and immunologists to aid them in optimizing care for cancer patients. According to the company, users of the service follow their normal IHC slide staining process, then scan the slides and send the images to Flagship, which analyzes them with their proprietary image-analysis process. TissueInsight gives rapid, data-rich tissue interpretation and removes the inherent variability of subjective manual tissue scoring, the company said. Along with its CLIA-reportable results, TissueInsight tumor microenvironment data includes information on tumor infiltrating lymphocytes and macrophages, the company added.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.